Masimo Free Cash Flow 2010-2024 | MASI

Masimo free cash flow for the twelve months ending September 30, 2024 was , a year-over-year.

  • Masimo annual free cash flow for 2023 was $0.05B, a 314.1% decline from 2022.
  • Masimo annual free cash flow for 2022 was $-0.023B, a 109.79% decline from 2021.
  • Masimo annual free cash flow for 2021 was $0.239B, a 72.51% increase from 2020.

Masimo Free Cash Flow 2010-2024 | MASI

  • Masimo annual free cash flow for 2023 was $0.05B, a 314.1% decline from 2022.
  • Masimo annual free cash flow for 2022 was $-0.023B, a 109.79% decline from 2021.
  • Masimo annual free cash flow for 2021 was $0.239B, a 72.51% increase from 2020.
Related Stocks
Company NameMarket
Cap
Thermo Fisher Scientific (TMO)$197.6B
Intuitive Surgical (ISRG)$186.6B
Edwards Lifesciences (EW)$43.6B
Alcon (ALC)$41.5B
IQVIA Holdings (IQV)$34.8B
IDEXX Laboratories (IDXX)$33.5B
DexCom (DXCM)$29.6B
Waters (WAT)$21.4B
STERIS (STE)$20.2B
SONOVA HOLDING (SONVY)$19.4B
Hologic (HOLX)$16.1B
Fresenius Medical Care AG KGaA (FMS)$13.2B
Sysmex ADR (SSMXY)$11.7B
Globus Medical (GMED)$11.2B
Penumbra (PEN)$9.3B
Teleflex (TFX)$8.1B
Glaukos (GKOS)$7.9B
Integer Holdings (ITGR)$4.5B
PROCEPT BioRobotics (PRCT)$4.2B
Inari Medical (NARI)$3.2B
Veracyte (VCYT)$3B
Nihon Kohden (NHNKY)$2.6B
LivaNova (LIVN)$2.6B
Tandem Diabetes Care (TNDM)$2.2B
Elekta AB (EKTAY)$2.1B
TransMedics (TMDX)$2B
Integra LifeSciences Holdings (IART)$1.7B
RxSight (RXST)$1.5B
Alphatec Holdings (ATEC)$1.3B
Artivion (AORT)$1.2B